Xencor Inc. (XNCR)
NASDAQ: XNCRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
XNCR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.50B
- EPS (TTM)
- -$1.56
- Dividend yield
- None
- 52-week range
- 10.38 – 40.60
- Day range
- 33.12 – 34.27
- Volume / Avg
- 1.22M / 1.54M
- Beta
- —
- Shares outstanding
- 75.04M
52-week range
XNCR stock today
On Nov 20, XNCR ended the session at $33.26, shedding $0.75 (2.21%), versus the S&P 500's 3.70% decline. Shares are 18.1% below their 52-week high of $40.60, set on Nov 11, 2026 and 220.6% above the 52-week low of $10.38, in the middle of the past year's range. XNCR is up 117.2% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 109.6%.
Xencor has posted a net loss over the last twelve months (EPS of -$1.56), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Xencor
Company profileXencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; XmAb942, which is in clinical development for patients with Crohn's disease and ulcerative colitis; Plamotamab, a bispecific T-cell, which is in Phase Ib study to treat rheumatoid arthritis; and XmAb657 for patients with idiopathic inflammatory myopathies.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Bassil I. Dahiyat Ph.D.
- Headquarters
- Pasadena, CA
- Employees
- 260
- IPO year
- 2013
- Website
- xencor.com
Financial highlights
Full financialsIn fiscal 2025, Xencor generated $125.6 million in revenue, up 13.7% from fiscal 2024. Xencor reported a net loss of $91.9 million, compared with a loss of $232.6 million a year earlier. Operating margin was -141.4%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $125.58M | $110.49M | $174.62M | $164.58M | $275.11M |
| Growth | +13.65% | -36.72% | +6.10% | -40.18% | +124.23% |
| Net income | $-91.92M | $-232.62M | $-133.13M | $-55.18M | $82.63M |
| EPS (diluted) | $-1.24 | $-3.58 | $-2.20 | $-0.93 | $1.37 |
Analyst forecast
ForecastConsensus (14 analysts)
strong_buy
Avg. price target
$42.50+27.78%
- Strong buy 3
- Buy 9
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $0.50 vs $-0.35
- Surprise
- +242.86%
XNCR news
All XNCR news- Show Me The Money: Xencor (XNCR) Delivers Triple-Digit Gains, With XENITH-UC Poised For The Next ActNasdaqXNCR, BF.A
- Xencor, Inc. Reports Third Quarter 2026 Financial Results and Outlines Clinical Pipeline PlansNasdaq
- Xencor Reports Third Quarter 2026 Financial ResultsBusiness Wire
- Xencor Consensus Price Target Increased by 34.27% to $44.32Nasdaq
- Xencor soars 16% on encouraging early XmAb819 dataSeeking Alpha
- Three Movers And A Catalyst: SGRY, XNCR, ORKA Gain As Acumen Nears ALTITUDE-AD ReadoutNasdaqABOS, ORKA, SGRY, XNCR
- Xencor stock surges on positive cancer drug trial dataInvesting.com
- Xencor, Inc. Selects 400 mcg/kg as Proposed Recommended Phase 3 Dose for XmAb819 in Advanced Clear Cell Renal Cell CarcinomaNasdaq
Xencor peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IDYAIDEAYA Biosciences Inc. | 25.56 | -2.33% | $2.47B | vs XNCR |
| MBXMBX Biosciences Inc. | 49.55 | -7.23% | $2.46B | vs XNCR |
| ZLABZai Lab Limited ADR | 21.03 | -4.06% | $2.63B | vs XNCR |
| PBHPrestige Consumer Healthcare Inc. | 49.63 | +0.06% | $2.35B | vs XNCR |
| HCMHUTCHMED (China) Limited ADR | 13.22 | -1.71% | $2.30B | vs XNCR |
| RCUSArcus Biosciences Inc. | 15.62 | -1.01% | $2.25B | vs XNCR |
| PHVSPharvaris N.V. | 31.28 | -1.20% | $2.21B | vs XNCR |
| PRGOPerrigo Company plc | 15.94 | -0.62% | $2.21B | vs XNCR |
Indexes, lists and sector
Xencor stock FAQ
What is Xencor's stock price today?
XNCR last traded at $33.26 as of Nov 20, 4:00 PM EST, down 2.21% on the day. Prices are delayed at least 15 minutes.
Who is Xencor's CEO?
Dr. Bassil I. Dahiyat Ph.D. is the chief executive officer of Xencor Inc., which has about 260 employees.
What is the XNCR 52-week high?
The 52-week high for XNCR is $40.60 and the 52-week low is $10.38. The stock is currently 18.1% below its high.